Barclays
FHTX icon

Barclays’s Foghorn Therapeutics FHTX Stock Holding History

Barclays’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$103K Buy
28,766
+9,577
+50% +$50.4K ﹤0.01% 4294
2026
Q2 		$93.6K Sell
19,189
-244
-1% -$1.08K ﹤0.01% 4064
2026
Q1 		$92.9K Sell
19,433
-43,757
-69% -$240K ﹤0.01% 4053
2025
Q4 		$341K Buy
63,190
+4,704
+8% +$21.3K ﹤0.01% 4067
2025
Q3 		$286K Sell
58,486
-12,328
-17% -$65.4K ﹤0.01% 4136
2025
Q2 		$333K Buy
70,814
+30,924
+78% +$129K ﹤0.01% 3988
2025
Q1 		$146K Sell
39,890
-11,719
-23% -$53.4K ﹤0.01% 4228
2024
Q4 		$244K Buy
51,609
+11,689
+29% +$85.2K ﹤0.01% 4215
2024
Q3 		$372K Buy
39,920
+26,228
+192% +$190K ﹤0.01% 3954
2024
Q2 		$78.7K Sell
13,692
-5,550
-29% -$33.1K ﹤0.01% 4022
2024
Q1 		$129K Sell
19,242
-13,662
-42% -$75.8K ﹤0.01% 4335
2023
Q4 		$212K Buy
32,904
+29,341
+823% +$127K ﹤0.01% 4392
2023
Q3 		$17.8K Sell
3,563
-508
-12% -$3.92K ﹤0.01% 4203
2023
Q2 		$28.7K Sell
4,071
-6,055
-60% -$42.3K ﹤0.01% 4053
2023
Q1 		$62.8K Buy
10,126
+4,729
+88% +$31K ﹤0.01% 4369
2022
Q4 		$34.4K Buy
5,397
+4,545
+533% +$34.3K ﹤0.01% 4673
2022
Q3 		$7K Sell
852
-156
-15% -$2.01K ﹤0.01% 4417
2022
Q2 		$14K Sell
1,008
-2,170
-68% -$28K ﹤0.01% 4516
2022
Q1 		$48K Buy
+3,178
New +$43.6K ﹤0.01% 4132

Other funds holding FHTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Barclays's FHTX Position: Q3 2026 in Review

Barclays increased its Foghorn Therapeutics (FHTX) stake by 50% in Q3 2026, buying an estimated $50.4K and bringing the position to 28,766 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #4294.

Barclays first reported a position in FHTX in Q1 2022 and has held it in 19 quarters since. The position peaked at $372K in Q3 2024. 44 funds tracked by Wall St. Rank hold FHTX as of Q3 2026.

  • Barclays held 28,766 shares of Foghorn Therapeutics worth $103K as of Q3 2026.
  • Barclays bought 9,577 Foghorn Therapeutics shares in Q3 2026, an estimated $50.4K.
  • Foghorn Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4294 holding.
  • Barclays first reported a position in Foghorn Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Foghorn Therapeutics position peaked at $372K in Q3 2024.
  • 44 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.